

**This item is the archived peer-reviewed author-version of:**

Ocular surface homeostasis after scleral lens usage

**Reference:**

Ballet Brice, Behaegel Joséphine, Reppe Sjur, Consejo Alejandra, Aass Hans Christian, Utheim Tor Paaske, Koppen Carina, Ní Dhubhghaill Sorcha.- Ocular surface homeostasis after scleral lens usage

Eye & contact lens: science and clinical practice- ISSN 1542-233X - 49:11(2023), p. 459-463

Full text (Publisher's DOI): <https://doi.org/10.1097/ICL.0000000000001027>

To cite this reference: <https://hdl.handle.net/10067/2011680151162165141>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

## Ocular Surface Homeostasis After Scleral Lens Usage

Brice Ballet<sup>1,2</sup>, MD; Josephine Behaegel<sup>1</sup>, MD, PhD; Sjur Reppe, PhD<sup>3,4</sup>; Alejandra Consejo<sup>5</sup>, PhD; Hans Christian Aass, PhD<sup>3</sup>; Tor Paaske Utheim, MD, PhD<sup>3,4</sup>; Carina Koppen<sup>1,2</sup>, MD, PhD; Sorcha Ní Dhubhghaill<sup>1,2</sup>, MD, PhD.

1 Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium

2 Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium

3 Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway

4 Department of Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway

5 Department of Applied Physics, University of Zaragoza, Zaragoza, Spain

**Corresponding author:** Dr. Brice Ballet; Department of Ophthalmology, Antwerp University Hospital, Drie Eikenstraat 655, 2650 Edegem, Belgium

Email: [brice.ballet@uza.be](mailto:brice.ballet@uza.be)

Telephone number: + 32 3 821 42 10

Fax: +32 3 825 19 26

**Short Title:** Tear film inflammatory changes after scleral contact lens wear

Article contents: 1 figure and 2 tables

Date of submission: Monday 13 March 2023

Date of revision: Thursday 8 June 2023

**Key words:** Scleral contact lens; inflammation; cytokine; tear film

**Acknowledgements and Financial Disclosure:** This study was realized by a Fund for Research in Ophthalmology (FRO) grant. The authors would like to thank Microlens Contactlens Technology b.v. (Arnhem, The Netherlands) and Maarten Van Hoey for providing and fitting the contact lenses used in this study.

No author has a financial or proprietary interest in any material or method mentioned.

---

27 **ABSTRACT**

28 **Objectives:** The aim of this prospective study is to examine the effects of five hours of well fitted  
29 mini-scleral contact lens (mini-SL) wear on the tear film cytokine expression in healthy eyes.

30 **Methods:** Twenty-three healthy participants were included in the study. One eye of each participant  
31 was selected at random and a mini-SL measuring 16.5 mm in diameter was fitted by an experienced  
32 contact lens specialist. The contact lens remained in place for five hours. Pre-corneal tear fluid was  
33 collected using capillary tubes at three different time-points: baseline before SL insertion (T0),  
34 after five hours of SL wear (T1), and three hours after SL removal (T2). The concentration of 40  
35 inflammatory cytokines at the three different time points was determined by using multiplex bead  
36 assay.

37 **Results:** Mini-scleral lens wear did not result in significant changes in the cytokine-to-protein  
38 ratio after five hours of wear on a healthy eye.

39 **Conclusions:** While a well-fitted mini-SL reduces the rate at which the pre-corneal tear film is  
40 refreshed, five hours of lens wear did not appear to significantly affect the tears cytokine to protein  
41 ratio, suggesting that scleral lenses have minimal impact on corneal cytokine expression.

---

## 42 INTRODUCTION

43 Scleral contact lenses (SLs) are large-diameter contact lenses designed to vault the cornea and  
44 limbus, with the haptic landing zone bearing entirely on the sclera and overlying conjunctiva.<sup>1</sup>  
45 While the concept of scleral contact lenses is not new, with some examples dating back to the  
46 19<sup>th</sup> century, it is only in the past two decades that technological improvements have made these  
47 large lenses a viable option for patients. The initial attempts using originally glass lenses were  
48 disappointing as they tended to induce visually significant corneal oedema due to relative  
49 hypoxia. This hypoxic reaction was not immediate but developed over a number of hours of lens  
50 wear and was referred to by names such as Müller's Mist and Fick's phenomenon <sup>2</sup>.

51 Adaptations to improve scleral lens oxygenation by allowing turnover of the tear film under the  
52 lens were attempted by use of flatter haptics or fenestrations, though these changes were often  
53 made at the expense of patient comfort <sup>3</sup>. Improvements in highly oxygen permeable materials  
54 have meant that modern scleral contact lenses can be affixed to the eye, form a seal, and avoid  
55 the development of oedema for the most part. While overt signs of corneal edema are not seen,  
56 it is possible that preventing the refreshment of the pre-corneal tear film can have more subtle,  
57 deleterious effects. In older eyes, or those with reduced endothelial cell counts, the development  
58 of corneal edema can still be seen, suggesting that there is still a degree of hypoxia induced by  
59 modern contact lenses <sup>4</sup>.

60 Mini-scleral contact lenses (mini-SLs) are a sub-group of scleral contact lenses, smaller than  
61 their predecessors, with a total lens diameter between 15 and 18mm.<sup>5</sup> They are primarily used  
62 for the correction of corneal surface irregularities that are difficult to correct with standard  
63 spectacle or contact lens correction (e.g. keratoconus <sup>6</sup>, post-penetrating keratoplasty <sup>7</sup>), or as  
64 a therapeutic option for ocular surface diseases including Sjögren syndrome<sup>8</sup>, exposure  
65 keratopathy<sup>9</sup>, and Stevens-Johnson Syndrome<sup>10</sup>. In terms of physiological interaction, mini-SLs  
66 still differ considerably from other types of contact lenses as they limit the tear exchange  
67 underneath the lens, like the original scleral lenses <sup>11</sup>.

68 To date, only limited studies have been conducted examining the corneal response to mini-SL  
69 wear, showing minimal central corneal swelling <sup>4,12</sup>. While some recent studies have investigated  
70 the impact of scleral lenses on corneal thickness and topography <sup>13,14</sup>, little is known about the  
71 biochemical effect of these lenses on the ocular surface. Lens thickness, the partially static post-  
72 lens reservoir and the minimal tear exchange are potential hypoxic drives inherent in the lens  
73 design, and therefore can potentially compromise ocular health. A reduced oxygenation may

---

74 affect cell metabolism, cause tissue swelling, loss of corneal transparency, and/or promote  
75 corneal neovascularization <sup>15</sup>.

76 In this study, we aimed to examine the cytokine response (i.e., the concentration of pro-  
77 inflammatory cytokines) of the ocular surface during and after mini-SL wear, to determine  
78 whether a potentially reduced refreshment of the pre-corneal tear film and concentration of  
79 oxygen can have a knock-on effect on ocular inflammation. Determining the potential for scleral  
80 lenses to induce elements of the inflammatory cascade might provide additional insight into the  
81 safety and efficacy of these devices.

82

### 83 **PATIENTS AND METHODS**

84 This prospective study was approved by the Antwerp University Hospital research ethics  
85 committee and adhered to the tenets of the Declaration of Helsinki (Belgian Federal Agency for  
86 Medicines and Health Products registry number B300201732868). Written informed consent  
87 was obtained from all 23 participants after explanation of the nature and possible consequences  
88 of the study.

#### 89 **Inclusion and Exclusion Criteria**

90 The inclusion criteria included a lack of ocular abnormalities (other than refractive errors), a  
91 corrected distance visual acuity (CDVA) of 20/20 or better, and no regular contact lens wearing  
92 history. The exclusion criteria included eyes with trauma, active allergies, ectasia, conjunctival  
93 lesions (for example pterygium), iatrogenic diseases, use of any topical medications other than  
94 artificial tears, or any surgery history, including refractive surgery, keratoplasty, and intrastromal  
95 ring segments. Presence or absence of these criteria was assessed by slit lamp examination.  
96 Patients were screened for dry eye disease using the validated Ocular Surface Disease Index  
97 (OSDI) questionnaire <sup>16</sup>.

#### 98 **Scleral Contact Lens Fitting**

99 All mini-SL fittings were performed by the same experienced optometrist (MVH). The SL design  
100 applied for all participants was miniMISA SL (Microlens, Arnhem, Netherlands) with spherical  
101 haptic landing zone. The SLs were all made of highly gas-permeable materials with an oxygen  
102 permeability (Dk) of 125, central thickness of 300 µm, a diameter of 16.5 mm, base curve radius  
103 of 7.8 mm and scleral curve of 13.5 mm.

---

104 The SL filled with preservative-free saline (Braun Mini Plasco physiologic NaCl 0.9%) was placed  
105 on a randomly determined eye for each participant. The position and vault were evaluated by  
106 slit-lamp examination and optical coherence tomography (OCT, [figure 1](#)). If regions of corneal  
107 bearing were observed, the sagittal depth of the lens was increased by 125  $\mu\text{m}$  increments and  
108 the fit reassessed until proper placement was achieved. In cases where the contact lens caused  
109 discomfort despite optimal fitting, the lens was removed, and the participant was excluded from  
110 the study.

### 111 **Tear Sample Collection**

112 The tear sample collection was conducted on the same day SLs were properly fitted. The tear  
113 fluid samples were collected by the same experienced clinician at three time points: 1) The  
114 baseline samples (T0), which were obtained before SLs fitting by using a 30  $\mu\text{L}$  glass capillary  
115 tube (Drummond Microcaps disposable pipets) applied to the tear meniscus at the lateral  
116 inferior fornix; 2) The samples after five hours of continuous well-fitted SLs wearing (T1), which  
117 were collected by capillary tube from the post-wear lens reservoir; 3) The samples three hours  
118 after SL removal (T2), with identical collection method as T0. Once obtained, the samples  
119 were transferred into cryovials (Sarstedt screw cap micro tubes 0.5 mL) and promptly stored at  
120  $-80\text{ }^{\circ}\text{C}$ . Transport with temperature monitoring was organized via a biopharmaceutical courier  
121 service (World Courier, Zaventem, Belgium) and took place one month after final specimen  
122 collection.

### 123 **Tear Fluid Analyses**

124 The Cytokine profiling of the collected tear fluid was performed at the Department of Medical  
125 Biochemistry of the Oslo University Hospital.

126 Prior to analyses, the samples were diluted with phosphate-buffered saline (PBS) and the protein  
127 concentration was measured according to recommendations from the manufacturer (Thermo  
128 Scientific, Rockford, IL, US). Second, the samples were transferred into fresh tubes and diluted  
129 with PBS containing bovine serum albumin (final BSA concentration 0.5%). Then, all samples  
130 were centrifuged at 10 000 g for 10 minutes at  $4^{\circ}\text{C}$ , and 25  $\mu\text{L}$  of the supernatants were loaded  
131 onto 96 well plates.

132 Finally, the multiplex analysis was performed according to a previously published protocol <sup>17</sup>.  
133 The broad screening kit was used for the analysis (Bio-Plex Pro Human Cytokine 40-plex Assay,  
134 Cat. No. 171AK99MR2, Bio-Rad Laboratories, Inc.) and included targets against: IL (interleukin)-  
135 1B, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16l; (C-C Motif Chemokine Ligand) CCL1, CCL2 (also referred

---

136 to as MCP-1), CCL3, CCL7, CCL8, CCL11, CCL13, CCL15 (also called MIP-1d), CCL17,  
137 CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27; CXCL (C-X-C Motif  
138 Chemokine Ligand)1, CXCL2, CXCL5, CXCL6, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13,  
139 CXCL16, CX3CL1 (also known as fractalkine), tumor necrosis factor (TNF- $\alpha$ ), interferon gamma  
140 (IFN- $\gamma$ ), granulocyte-macrophage colony-stimulating factor (GM-CSF), and macrophage  
141 migration inhibitory factor (MIF) . All values obtained from the assay were in an acceptable range  
142 according to recommendations from the manufacturer (intra-percent coefficient of variation <11  
143 and inter-percent coefficient of variation >21).

144 Since some samples did not contain any fluid (due to the evaporation during transportation), the  
145 cytokine concentration could not be determined, and instead the cytokine-to-protein ratio was  
146 calculated. The mean value  $\pm$  standard deviation (SD) of all adjusted cytokine levels (pg  
147 cytokine/ug protein) was calculated for the three timepoints under analysis.

#### 148 **Statistical analysis**

149 Statistical analysis was performed using SPSS software (Version 24.0; SPSS Inc., Chicago,  
150 Illinois, United States). One-way repeated measurements (ANOVA) with Bonferroni correction  
151 to control type-one error was used to assess differences within sessions. A significance level  $\alpha$   
152 of 0.05 was considered for all tests.

153

### 154 **RESULTS**

#### 155 **Demographics**

156 A total of 23 healthy volunteers (15 females and 8 males) aged between 18 and 45 years were  
157 included in this study. One male subject was excluded due to an insufficient tear volume  
158 sample. 40% of study subjects had a history of occasional soft contact lens use; none reported  
159 previous scleral lens wear ([table 1](#)).

#### 160 **Dry eye symptoms**

161 None of the subjects had significant dry eye disease, as substantiated by an OSDI of  $1,3 \pm 1,2$   
162 (mean  $\pm$  SD).

163

---

164 **Contact lens discomfort**

165 When comparing the data pool of subjects that reported contact lens discomfort during scleral  
166 wear (N = 5) against the data pool that did not report any symptoms, no statistically significant  
167 differences in cytokine concentration was found between sessions (t0 vs t0, t1 vs t1 and t2 vs  
168 t2).

169 **Cytokine levels**

170 *Interleukins*

171 No statistically significant difference in cytokine level was found between the three timepoints  
172 (t0, t1 and t2) for the interleukins IL-1B, IL-2, IL-4, IL-6, IL-8, IL-10, and IL-16.

173 *Chemokines*

174 No statistically significant difference in cytokine level was found between the three timepoints  
175 (t0, t1 and t2) for the CC-chemokines CCL1, CCL2, CCL3, CCL7, CCL8, CCL11, CCL13,  
176 CCL15, CCL17, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, nor  
177 for the CXC-chemokines CXCL1, CXCL2, CXCL5, CXCL6, CXCL9, CXCL10, CXCL11,  
178 CXCL12, CXCL13, CXCL16, and CX3CL1 (fractalkine).

179 *Other cytokines*

180 No statistically significant difference in cytokine level was found between the three timepoints  
181 (t0, t1 and t2) for TNF- $\alpha$ , IFN- $\gamma$ , GM-CSF and MIF.

182 ([table 2](#))

183

184 **DISCUSSION**

185 While indications for scleral lens use have been expanding over the years, little is known about  
186 the relationship between these contact lenses and the inflammatory state of the eye. In our  
187 study, no significant alteration in cytokine concentration could be detected after five hours of  
188 lens wear, suggesting that scleral lenses have little to no impact on short term ocular surface  
189 cytokine expression.



---

190 Irrespective of contact lens wear, the use of tear biomarkers to monitor pathological ocular  
191 conditions has been extensively studied over the last few years. For instance, there is  
192 mounting evidence that inflammation plays a key role in the pathogenesis of dry eye and  
193 ocular surface disease (OSD), with tear film analysis showing increased levels of IL-1, IL-6, IL-  
194 8, CX3CL1 and TNF- $\alpha$  <sup>18 19 20 21</sup>. These findings were substantiated by the most recent reports  
195 of the Dry Eye Workshop Study (DEWS II) which included ocular surface inflammation into the  
196 definition of this multifactorial pathology <sup>22</sup>. The same inflammatory cytokines were shown to  
197 be elevated in patients with Sjögren syndrome <sup>23</sup>. In addition, studies analyzing tear film  
198 composition in keratoconus have found increased levels of interleukin-6 (IL-6), tumor necrosis  
199 factor- $\alpha$ (TNF- $\alpha$ ), and matrix metalloproteinase (MMP)-9. Along the same lines, eye rubbing, a  
200 proven risk factor for keratoconus, has also been shown recently to increase tear levels of  
201 MMP-13, IL-6, and TNF- $\alpha$ . These findings suggest that keratoconus could be, at least in part,  
202 an inflammatory condition <sup>24</sup>. Moreover, several pro-inflammatory cytokines including IL-1b, IL-  
203 9 and IL-17A were found to be significantly elevated in tear fluid from aniridia patients.  
204 Increased inflammation of the ocular surface may be a factor in the development of MGD in  
205 these patients <sup>17</sup>.

206 In our review of the literature, we discovered only one study, recently published by Walker and  
207 colleagues, addressing the tear film cytokine composition with SL use in a group of healthy,  
208 soft contact lens wearers <sup>25</sup>. The researchers determined the concentration of several  
209 inflammatory biomarkers (IL-4, IL-8, MMP-9, and MMP-10) present in the scleral lens fluid  
210 reservoir and basal tear samples. Results showed greater concentrations of MMP-9 and -10 in  
211 the fluid reservoir in comparison to the basal tear samples, while no significant difference in IL-  
212 4 and IL-8 could be noted. However, since that study compared the tears beneath and outside  
213 of the scleral lens (at the same time point), rather than pre- and post-wear as in our study  
214 design, caution should be exercised juxtaposing these results. Additionally, while our array  
215 contained a wider range of inflammatory cytokines, it did not include MMP's.

216 Another study by Carracedo et al assessed short-term scleral lens wear in keratoconus  
217 patients, showing these lenses could improve signs and symptoms of dry eye. The authors  
218 also discovered an increase of MMP-9 concentration in the precorneal fluid reservoir,  
219 attributing this finding to tear film stagnation <sup>26</sup>.

220 Considering the findings in both studies, we hypothesize the relative increase in MMP levels to  
221 be explained by tear accumulation between contact lens and ocular surface, rather than a de

---

222 facto increased synthesis of inflammatory enzymes. This would be consistent with the fact that  
223 there is a minimum tear exchange in most participants fitted with SLs <sup>27</sup>.

224 We found no correlation between contact lens discomfort and inflammatory mediators in the  
225 tear film. In fact, comfort was highly variable, with approximately one out of five subjects  
226 reporting some discomfort after five hours of lens wear. This is likely explained by our subjects  
227 being either contact lens novices or being only accustomed to soft contact lenses, which are  
228 typically more comfortable. It also clarifies why some studies report improved comfort using  
229 scleral lenses in ocular surface disease <sup>28</sup>, as these diseased eyes have a different baseline  
230 (already being in discomfort) and also a higher likelihood of having been exposed to less  
231 comfortable alternatives such as RGP lenses.

232 We acknowledge some limitations to this study. First, since all participants were young and  
233 healthy with a normal cornea and no history of ocular disease, these results must be  
234 interpreted with caution, as they may not be applicable to older patients or those with ocular  
235 surface abnormalities. However, performing these tests on diseased eyes, known to already  
236 have cytokine changes, would have induced far greater variability. In addition, inflammatory  
237 mediators could hypothetically have become trapped in the lens reservoir, further disrupting  
238 our findings, and compromising ocular surface integrity. Our data, derived from normal  
239 individuals, allows for controlled normative data to be plotted, which in turn can be used in  
240 future studies with similar design on diseased eyes.

241 Furthermore, it is possible that inflammatory changes only occur after a longer period of lens  
242 wear, so a longer study period might be needed to detect any changes. Finally, an additional  
243 limitation of the study is that only one lens design was used (mini-scleral). Therefore, longer term  
244 studies, examining both healthy eyes and eyes with compromised corneas, are required to  
245 understand the influence of extended miniscleral contact lens wear on corneal physiology, and  
246 to elucidate the involved inflammatory pathways.

## 247 **CONCLUSION**

248 To our knowledge, this is the first study to examine the biochemical changes to the ocular surface  
249 in response to scleral lens wear over time. Our results show that five hours of mini-SL wear is  
250 not associated with a change in corneal tear film cytokine levels, suggesting that these lenses  
251 have little to no impact on short term ocular surface cytokine expression in healthy eyes.  
252 Subsequent studies should continue to evaluate inflammation during scleral lens wear,  
253 particularly in diseased eyes.

---

254 **REFERENCES**

- 255 1. Schornack MM. Scleral lenses: a literature review. *Eye & contact lens* 2015;41:3-11.
- 256 2. Vincent SJ, Fadel D. Optical considerations for scleral contact lenses: A review. *Contact*  
257 *lens & anterior eye : the journal of the British Contact Lens Association* 2019;42:598-613.
- 258 3. Pullum KW, Whiting MA, Buckley RJ. Scleral Contact Lenses: The Expanding Role.  
259 *Cornea* 2005;24:269-77.
- 260 4. Vincent SJ, Alonso-Caneiro D, Collins MJ. Corneal changes following short-term  
261 miniscleral contact lens wear. *Contact lens & anterior eye : the journal of the British Contact*  
262 *Lens Association* 2014;37:461-8.
- 263 5. van der Worp E, Bornman D, Ferreira DL, Faria-Ribeiro M, Garcia-Porta N, Gonzalez-  
264 Meijome JM. Modern scleral contact lenses: A review. *Contact lens & anterior eye : the journal*  
265 *of the British Contact Lens Association* 2014;37:240-50.
- 266 6. Koppen C, Kreps EO, Anthonissen L, Van Hoey M, Dhubhghaill SN, Vermeulen L.  
267 Scleral Lenses Reduce the Need for Corneal Transplants in Severe Keratoconus. *Am J*  
268 *Ophthalmol* 2018;185:43-7.
- 269 7. Barnett M, Lien V, Li JY, Durbin-Johnson B, Mannis MJ. Use of Scleral Lenses and  
270 Miniscleral Lenses After Penetrating Keratoplasty. *Eye & contact lens* 2016;42:185-9.
- 271 8. Schornack MM, Pyle J, Patel SV. Scleral lenses in the management of ocular surface  
272 disease. *Ophthalmology* 2014;121:1398-405.

- 
- 273 9. Grey F, Carley F, Biswas S, Tromans C. Scleral contact lens management of bilateral  
274 exposure and neurotrophic keratopathy. *Contact lens & anterior eye : the journal of the British*  
275 *Contact Lens Association* 2012;35:288-91.
- 276 10. Rathi VM, Taneja M, Dumpati S, Mandathara PS, Sangwan VS. Role of Scleral Contact  
277 Lenses in Management of Coexisting Keratoconus and Stevens-Johnson Syndrome. *Cornea*  
278 2017;36:1267-9.
- 279 11. Ko L, Maurice D, Ruben M. Fluid exchange under scleral contact lenses in relation to  
280 wearing time. *Br J Ophthalmol* 1970;54:486-9.
- 281 12. Compan V, Oliveira C, Aguilera-Arzo M, Molla S, Peixoto-de-Matos SC, Gonzalez-  
282 Meijome JM. Oxygen diffusion and edema with modern scleral rigid gas permeable contact  
283 lenses. *Investigative ophthalmology & visual science* 2014;55:6421-9.
- 284 13. Consejo A, Behaegel J, Van Hoey M, Wolffsohn JS, Rozema JJ, Iskander DR. Anterior  
285 eye surface changes following miniscleral contact lens wear. *Contact lens & anterior eye : the*  
286 *journal of the British Contact Lens Association* 2019;42:70-4.
- 287 14. Consejo A, Behaegel J, Van Hoey M, Iskander DR, Rozema JJ. Scleral asymmetry as a  
288 potential predictor for scleral lens compression. *Ophthalmic and Physiological Optics*  
289 2018;38:609-16.
- 290 15. Michaud L, van der Worp E, Brazeau D, Warde R, Giasson CJ. Predicting estimates of  
291 oxygen transmissibility for scleral lenses. *Contact lens & anterior eye : the journal of the British*  
292 *Contact Lens Association* 2012;35:266-71.
- 293 16. Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and  
294 Validity of the Ocular Surface Disease Index. *Archives of Ophthalmology* 2000;118:615-21.

- 
- 295 17. Landsend ECS, Utheim OA, Pedersen HR, et al. The Level of Inflammatory Tear  
296 Cytokines is Elevated in Congenital Aniridia and Associated with Meibomian Gland  
297 Dysfunction. *Investigative ophthalmology & visual science* 2018;59:2197-204.
- 298 18. Na KS, Mok JW, Kim JY, Rho CR, Joo CK. Correlations between tear cytokines,  
299 chemokines, and soluble receptors and clinical severity of dry eye disease. *Investigative*  
300 *ophthalmology & visual science* 2012;53:5443-50.
- 301 19. Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine  
302 analysis and clinical correlations in evaporative-type dry eye disease. *Mol Vis* 2010;16:862-73.
- 303 20. Lam H, Bleiden L, de Paiva CS, Farley W, Stern ME, Pflugfelder SC. Tear cytokine  
304 profiles in dysfunctional tear syndrome. *Am J Ophthalmol* 2009;147:198-205. e1.
- 305 21. Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of  
306 inflammatory cytokines in the tears of dry eye patients. *Cornea* 2009;28:1023-7.
- 307 22. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. *Ocul*  
308 *Surf* 2017;15:438-510.
- 309 23. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the  
310 tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. *Curr*  
311 *Eye Res* 1999;19:201-11.
- 312 24. Galvis V, Sherwin T, Tello A, Merayo J, Barrera R, Acera A. Keratoconus: an  
313 inflammatory disorder? *Eye (Lond)* 2015;29:843-59.
- 314 25. Walker MK, Lema C, Redfern R. Scleral lens wear: Measuring inflammation in the  
315 fluid reservoir. *Contact Lens and Anterior Eye* 2020;43:577-84.

- 
- 316 26. Carracedo G, Blanco MS, Martin-Gil A, Zicheng W, Alvarez JC, Pintor J. Short-term  
317 Effect of Scleral Lens on the Dry Eye Biomarkers in Keratoconus. *Optom Vis Sci* 2016;93:150-  
318 7.
- 319 27. Tse V, Tan B, Kim YH, Zhou Y, Lin MC. Tear dynamics under scleral lenses. *Contact*  
320 *Lens and Anterior Eye* 2019;42:43-8.
- 321 28. Harthan JS, Shorter E. Therapeutic uses of scleral contact lenses for ocular surface  
322 disease: patient selection and special considerations. *Clin Optom (Auckl)* 2018;10:65-74.
- 323
- 324

---

325 **Figure 1**

326 Optical coherence tomography (OCT) of a well-fitted mini-scleral lens, as demonstrated by a  
327 complete vault of the central cornea and a haptic landing zone on the sclera.

328

---

329 **Table 1**

330 Demographic data of the subject population.



---

331 **Table 2**

332 Mean value  $\pm$  standard deviation and statistical significance of all adjusted cytokine levels (pg  
333 cytokine/ug protein) for the three stages under analysis.

**Table 1**

Demographics of the subject population.

<b>Subjects included</b>	N = 22
<b>Mean Age <math>\pm</math> SD</b>	30 $\pm$ 7,7
<b>Gender (% female)</b>	68
<b>Race</b>	White (20), Asian (2)
<b>History of soft contact lens use</b>	9 subjects

**Table 2**

Mean value  $\pm$  standard deviation and statistical significance of all adjusted cytokine levels (pg cytokine/ $\mu$ g protein) for the three stages under analysis.

Cytokine name	Baseline (t0)	Just before SCL removal (t1)	3 hours after SCL removal (t2)	P-value (one way ANOVA)
IL-1B	0.008 $\pm$ 0.005	0.009 $\pm$ 0.005	0.007 $\pm$ 0.007	0.800
IL-2	0.025 $\pm$ 0.019	0.032 $\pm$ 0.019	0.024 $\pm$ 0.023	0.581
IL-4	0.034 $\pm$ 0.023	0.043 $\pm$ 0.028	0.030 $\pm$ 0.021	0.308
IL-6	0.033 $\pm$ 0.024	0.033 $\pm$ 0.026	0.032 $\pm$ 0.028	0.988
IL-8/CXCL8	0.122 $\pm$ 0.241	0.036 $\pm$ 0.035	0.022 $\pm$ 0.015	0.056
IL-10	0.014 $\pm$ 0.007	0.014 $\pm$ 0.008	0.012 $\pm$ 0.010	0.730
IL-16	0.185 $\pm$ 0.112	0.217 $\pm$ 0.162	0.184 $\pm$ 0.174	0.786
TNF- $\alpha$	0.037 $\pm$ 0.019	0.036 $\pm$ 0.019	0.036 $\pm$ 0.029	0.978
IFN- $\gamma$	0.076 $\pm$ 0.050	0.089 $\pm$ 0.072	0.078 $\pm$ 0.075	0.841
GM-CSF	0.177 $\pm$ 0.096	0.207 $\pm$ 0.148	0.166 $\pm$ 0.162	0.757
MIF	0.727 $\pm$ 0.395	1.396 $\pm$ 1.836	0.800 $\pm$ 0.974	0.174
CCL1	0.071 $\pm$ 0.031	0.118 $\pm$ 0.130	0.077 $\pm$ 0.082	0.257
CCL2	0.023 $\pm$ 0.016	0.042 $\pm$ 0.041	0.034 $\pm$ 0.029	0.162
CCL3	0.011 $\pm$ 0.010	0.011 $\pm$ 0.010	0.010 $\pm$ 0.010	0.881
CCL7	0.171 $\pm$ 0.127	0.190 $\pm$ 0.150	0.171 $\pm$ 0.168	0.908
CCL8	0.006 $\pm$ 0.004	0.007 $\pm$ 0.006	0.007 $\pm$ 0.008	0.866
CCL11	0.039 $\pm$ 0.023	0.043 $\pm$ 0.036	0.040 $\pm$ 0.036	0.935
CCL13	0.010 $\pm$ 0.005	0.009 $\pm$ 0.006	0.009 $\pm$ 0.008	0.968

CCL15	0.232 ± 0.183	0.179 ± 0.127	0.210 ± 0.166	0.589
CCL17	0.071 ± 0.053	0.093 ± 0.061	0.076 ± 0.073	0.627
CCL19	0.219 ± 0.117	0.241 ± 0.143	0.205 ± 0.157	0.734
CCL20	0.088 ± 0.039	0.086 ± 0.050	0.076 ± 0.037	0.652
CCL21	1.530 ± 2.135	2.139 ± 2.139	1.264 ± 0.693	0.343
CCL22	0.072 ± 0.032	0.079 ± 0.086	0.071 ± 0.062	0.927
CCL23	0.038 ± 0.026	0.052 ± 0.044	0.043 ± 0.040	0.563
CCL24	0.165 ± 0.118	0.182 ± 0.155	0.171 ± 0.168	0.924
CCL25	0.637 ± 0.515	0.563 ± 0.477	0.634 ± 0.669	0.900
CCL26	0.068 ± 0.053	0.090 ± 0.080	0.062 ± 0.068	0.488
CCL27	0.086 ± 0.066	0.101 ± 0.056	0.101 ± 0.115	0.852
CXCL1	0.316 ± 0.208	0.470 ± 0.576	0.290 ± 0.343	0.336
CXCL2	0.111 ± 0.047	0.168 ± 0.213	0.120 ± 0.128	0.474
CXCL5	1.406 ± 0.880	1.749 ± 1.602	1.525 ± 1.470	0.762
CXCL6	0.090 ± 0.050	0.112 ± 0.110	0.074 ± 0.064	0.337
CXCL9	0.532 ± 0.551	0.510 ± 0.485	0.407 ± 0.368	0.665
CXCL10	2.977 ± 2.886	3.161 ± 2.528	2.698 ± 4.385	0.909
CXCL11	0.207 ± 0.185	0.172 ± 0.135	0.180 ± 0.201	0.804
CXCL12	0.444 ± 0.272	0.549 ± 0.442	0.471 ± 0.450	0.733
CXCL13	0.006 ± 0.003	0.010 ± 0.013	0.007 ± 0.007	0.296
CXCL16	0.021 ± 0.012	0.018 ± 0.013	0.020 ± 0.018	0.802
CX3CL1	0.321 ± 0.123	0.396 ± 0.223	0.319 ± 0.207	0.355

